Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 8/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367046 | 0.87 | JAK2 (0.77) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL3260453 | 0.84 | JAK2 (0.72) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL15796859 | 0.84 | JAK2 (0.72) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL2640430 | 0.83 | JAK2 (0.71) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL2254342 | 0.83 | JAK2 (0.72) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL2251442 | 0.83 | JAK2 (0.70) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL3260096 | 0.83 | JAK2 (0.70) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL2640589 | 0.82 | JAK2 (1.00) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL3261792 | 0.80 | JAK2 (0.66) | JAK2NUDT1JAK3JAK1PIK3CD | |
| SCHEMBL3260459 | 0.79 | JAK2 (0.65) | JAK2NUDT1JAK3JAK1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | JAK2 1/4885NUDT1 2601/4885JAK3 3/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK2 31/4885NUDT1 736/4885JAK3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.